{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T01:30:54Z","timestamp":1790559054534,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010051.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000}}],"reference-count":160,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010051.pub3","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T10:38:04Z","timestamp":1784284684000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Topical cyclosporine A therapy for dry eye disease"],"prefix":"10.1002","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7178-1412","authenticated-orcid":false,"given":"Smruti R","family":"Priyadarshini","sequence":"additional","affiliation":[{"name":"Cornea and Anterior Segment Services; L V Prasad Eye Institute; Bhubaneswar India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumen","family":"Sadhu","sequence":"additional","affiliation":[{"name":"School of Optometry and Vision Science; University of New South Wales; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Chen","family":"Tzang","sequence":"additional","affiliation":[{"name":"School of Medicine; National Taiwan University College of Medicine; Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carter","family":"Niedert","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus; Aurora CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian A","family":"Holt","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus; Aurora CO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genie","family":"Han","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bloomberg School of Public Health; Baltimore MD USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cintia S","family":"de Paiva","sequence":"additional","affiliation":[{"name":"Ophthalmology; Baylor College of Medicine; Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C","family":"Pflugfelder","sequence":"additional","affiliation":[{"name":"Ophthalmology; Baylor College of Medicine; Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esen K","family":"Akpek","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; Duke University School of Medicine; Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology; University of Colorado Denver Anschutz Medical Campus; Aurora Colorado USA"},{"name":"Department of Epidemiology; University of Colorado Denver Anschutz Medical Campus; Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD010051.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/opo.12888","article-title":"The global prevalence of dry eye disease: a Bayesian view","volume":"41","author":"Papas","year":"2021","journal-title":"Ophthalmic & Physiological Optics"},{"issue":"6","key":"10.1002\/14651858.CD010051.pub3-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1159\/000525696","article-title":"Prevalence and incidence of dry eye disease in Asia: a systematic review and meta-analysis","volume":"65","author":"Cai","year":"2022","journal-title":"Ophthalmic Research"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12886-023-03249-w","article-title":"Prevalence of dry eye and Meibomian gland dysfunction in Central and South America: a systematic review and meta-analysis","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD010051.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"101837","DOI":"10.1016\/j.clae.2023.101837","article-title":"The epidemiology of dry eye disease in the UK: the Aston Dry Eye Study","volume":"46","author":"Vidal-Rohr","year":"2023","journal-title":"Contact Lens and Anterior Eye"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jtos.2023.12.001","article-title":"Dry eye disease in the young: a narrative review","volume":"31","author":"Stapleton","year":"2024","journal-title":"Ocular Surface"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub3-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"e002014","DOI":"10.1136\/bmjophth-2024-002014","article-title":"Prevalence of dry eye disease among children: a systematic review and meta-analysis","volume":"10","author":"Zou","year":"2025","journal-title":"BMJ Open Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ajo.2025.05.040","article-title":"TFOS DEWS III digest report","volume":"279","author":"Stapleton","year":"2025","journal-title":"American Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD010051.pub3-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ophtha.2016.11.008","article-title":"Predictors of discordance between symptoms and signs in dry eye disease","volume":"124","author":"Vehof","year":"2017","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD010051.pub3-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1136\/bjophthalmol-2017-310633","article-title":"Epidemiology of discordance between symptoms and signs of dry eye","volume":"102","author":"Ong","year":"2017","journal-title":"British Journal of Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD010051.pub3-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.ophtha.2021.03.030","article-title":"Systemic conditions associated with severity of dry eye signs and symptoms in the DRy Eye Assessment and Management study","volume":"128","author":"Yu","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jtos.2020.11.009","article-title":"Sex and age differences in symptoms and signs of dry eye disease in a Norwegian cohort of patients","volume":"19","author":"Tellefsen N\u00f8land","year":"2021","journal-title":"Ocular Surface"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub3-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"100270","DOI":"10.1016\/j.xops.2023.100270","article-title":"Age associations with dry eye clinical signs and symptoms in the DRy Eye Assessment and Management (DREAM) Study","volume":"3","author":"Zhao","year":"2023","journal-title":"Ophthalmology Science"},{"issue":"9","key":"10.1002\/14651858.CD010051.pub3-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1001\/archopht.118.9.1264","article-title":"Prevalence of and risk factors for dry eye syndrome","volume":"118","author":"Moss","year":"2000","journal-title":"Archives of Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD010051.pub3-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.18240\/ijo.2016.07.17","article-title":"Metabolic syndrome risk factors and dry eye syndrome: a meta-analysis","volume":"9","author":"Tang","year":"2016","journal-title":"International Journal of Ophthalmology"},{"issue":"12","key":"10.1002\/14651858.CD010051.pub3-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1136\/bjophthalmol-2014-305201","article-title":"Prevalence and risk factors of dry eye disease in a British female cohort","volume":"98","author":"Vehof","year":"2014","journal-title":"British Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD010051.pub3-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocular Surface"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1517\/14728214.2011.537824","article-title":"Emerging drugs for uveitis","volume":"16","author":"Larson","year":"2011","journal-title":"Expert Opinion on Emerging Drugs"},{"issue":"16","key":"10.1002\/14651858.CD010051.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.2174\/0929867033457160","article-title":"Cyclophilin D as a drug target","volume":"10","author":"Waldmeier","year":"2003","journal-title":"Current Medicinal Chemistry"},{"issue":"Pt 1","key":"10.1002\/14651858.CD010051.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1042\/BJ20040669","article-title":"Cyclophilin-D promotes the mitochondrial permeability transition but has opposite effects on apoptosis and necrosis","volume":"383","author":"Li","year":"2004","journal-title":"Biochemical Journal"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/mi.2010.82","article-title":"Homeostatic control of conjunctival mucosal goblet cells by NKT-derived IL-13","volume":"4","author":"De Paiva","year":"2011","journal-title":"Mucosal Immunology"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub3-BIB0021|cit21","first-page":"337","article-title":"Flow cytometry in impression cytology during keratoconjunctivitis sicca: effects of topical cyclosporin A on HLA DR expression","volume":"26","author":"Galatoire","year":"2003","journal-title":"Journal Francais d'Ophtalmologie"},{"issue":"11","key":"10.1002\/14651858.CD010051.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/archopht.118.11.1489","article-title":"Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes","volume":"118","author":"Kunert","year":"2000","journal-title":"Archives of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/01.ico.0000133994.22392.47","article-title":"Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca","volume":"24","author":"Strong","year":"2005","journal-title":"Cornea"},{"issue":"9","key":"10.1002\/14651858.CD010051.pub3-BIB0024|cit24","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010051.pub2","article-title":"Topical cyclosporine A therapy for dry eye syndrome","author":"De Paiva","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0025|cit25","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological Expectations of Cochrane Intervention Reviews Cochrane: London, Version August 2023"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13643-019-1188-0","article-title":"How should systematic reviewers handle conference abstracts? A view from the trenches","volume":"8","author":"Scherer","year":"2019","journal-title":"Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD010051.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the Ocular Surface Disease Index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Archives of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD010051.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/ICL.0000000000000288","article-title":"Rasch analysis of the Standard Patient Evaluation of Eye Dryness questionnaire","volume":"43","author":"Asiedu","year":"2017","journal-title":"Eye & Contact Lens: Science & Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub3-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/s1542-0124(12)70053-8","article-title":"Development and validation of a short global dry eye symptom index","volume":"5","author":"Schaumberg","year":"2007","journal-title":"Ocular Surface"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub3-BIB0031|cit31","first-page":"130","article-title":"How to identify randomized controlled trials in MEDLINE: ten years on","volume":"94","author":"Glanville","year":"2006","journal-title":"Journal of the Medical Library Association"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0032|cit32","unstructured":"Covidence Veritas Health Innovation 2025"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0033|cit33","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0034|cit34","unstructured":"Risk of bias 2: frequently asked questions https:\/\/methods.cochrane.org\/risk-bias-2-faqs?utm_source=chatgpt.com"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0035|cit35","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v5.1.0"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0036|cit36","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Chapter 10: Analysing data and undertaking meta-analyses [last updated November 2024]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0037|cit37","unstructured":"McKenzie JE Brennan SE Ryan RE Thomson HJ Johnston RV Chapter 9: Summarizing study characteristics and preparing for synthesis [last updated October 2019]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from cochrane.org\/handbook."},{"issue":"4","key":"10.1002\/14651858.CD010051.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5958\/0976-5506.2019.00681.8","article-title":"Comparative study of CMC 0.5% eye drops versus combination of.05% cyclosporin ophthalmic emulsion and 0.5% CMC eye drops in dry eye disorders","volume":"10","author":"Agarwal","year":"2019","journal-title":"Indian Journal of Public Health Research and Development"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0039|cit39","unstructured":"Topical cyclosporine for the treatment of dry eye in patients infected with the human immunodeficiency virus clinicaltrials.gov\/study\/NCT00797030"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1590\/S0034-72802009000200004","article-title":"Topical cyclosporine 0.05% for the treatment of dry eye disease in patients infected with the human immunodeficiency virus","volume":"68","author":"Barreto","year":"2009","journal-title":"Revista Brasileira de Oftalmologia"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/jop.2022.0119","article-title":"A multicenter, randomized, double-blind evaluation of the efficacy of TJO-087 versus 0.05% cyclosporine A in moderate to severe dry eye","volume":"39","author":"Eom","year":"2023","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0042|cit42","unstructured":"Evaluating the efficacy and safety of TJO-087 in moderate to severe dry eye disease patients clinicaltrials.gov\/study\/NCT05245604"},{"issue":"12","key":"10.1002\/14651858.CD010051.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.18240\/ijo.2022.12.05","article-title":"Clinical efficacy of 0.05% cyclosporine nano-emulsion in the treatment of dry eye syndrome associated with meibomian gland dysfunction","volume":"15","author":"Jo","year":"2022","journal-title":"International Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0044|cit44","unstructured":"The efficacy of 0.05% cyclosporin eye drop for dry eye disease trialsearch.who.int\/Trial2.aspx?TrialID=KCT0006923"},{"issue":"3","key":"10.1002\/14651858.CD010051.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.clinthera.2020.12.023","article-title":"Efficacy, safety, and tolerability of a novel cyclosporine, a formulation for dry eye disease: a\u2002multicenter phase II clinical study","volume":"43","author":"Peng","year":"2021","journal-title":"Clinical Therapeutics"},{"issue":"28","key":"10.1002\/14651858.CD010051.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3126\/nepjoph.v14i2.38928","article-title":"Safety and efficacy of cyclosporine (0.05% versus 0.09%) in dry eye disease. Is it the strength of cyclosporin that really matters?","volume":"14","author":"Rajpoot","year":"2022","journal-title":"Nepalese Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0047|cit47","unstructured":"To compare safety and efficacy of cyclosporine 0.05% and cyclosporine 0.09% eyedrops for dry eye trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-UMIN000035991"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0048|cit48","first-page":"254","article-title":"Efficacy of a 0.05% cyclosporine a topical nanoemulsion in dry eyes with obstructive meibomian gland dysfunction","volume":"3","author":"Rhim","journal-title":"Japanese Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0049|cit49","unstructured":"Clinical trial on the evaluation of cyclosporine eye drop for dry eye patients with meibomian gland dysfunction trialsearch.who.int\/Trial2.aspx?TrialID=KCT0004199"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1089\/jop.2020.0104","article-title":"A randomized, placebo-controlled phase II clinical trial of 0.01% or 0.02% cyclosporin A with 3% trehalose in patients with dry eye disease","volume":"37","author":"Shin","year":"2021","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0051|cit51","unstructured":"Efficacy and safety study of hu00701\/\u200bhu007 eye drops in patients with dry eye syndrome clinicaltrials.gov\/study\/NCT02917512"},{"issue":"6","key":"10.1002\/14651858.CD010051.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ophtha.2019.01.024","article-title":"A clinical phase II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease","volume":"126","author":"Wirta","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0053|cit53","unstructured":"CyclASol for the treatment of moderate to severe dry-eye disease clinicaltrials.gov\/study\/NCT02617667"},{"issue":"36","key":"10.1002\/14651858.CD010051.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"e34923","DOI":"10.1097\/MD.0000000000034923","article-title":"A randomized controlled trial involving college student: comparing 0.15% hyaluronic acid with 0.05% cyclosporine A and 3% diquafosol sodium in the treatment of dry eye","volume":"102","author":"Xu","year":"2023","journal-title":"Medicine"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0055|cit55","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials [last updated October 2019]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0056|cit56","unstructured":"McKenzie JE Brennan SE Chapter 12: Synthesizing and presenting findings using other methods [last updated October 2019]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF02697322","article-title":"Effect of topical cyclosporine on tear functions in tear-deficient dry eyes","volume":"39","author":"Jain","year":"2007","journal-title":"Annals of Ophthalmology (Skokie, Ill.)"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0161-6420(99)00176-1","article-title":"Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group","volume":"107","author":"Sall","year":"2000","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1002\/14651858.CD010051.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.ophtha.2005.05.013","article-title":"Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years","volume":"112","author":"Barber","year":"2005","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD010051.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archopht.120.3.330","article-title":"Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine","volume":"120","author":"Kunert","year":"2002","journal-title":"Archives of Ophthalmology"},{"issue":"11","key":"10.1002\/14651858.CD010051.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1001\/archopht.118.11.1489","article-title":"Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes","volume":"118","author":"Kunert","year":"2000","journal-title":"Archives of Ophthalmology"},{"issue":"5","key":"10.1002\/14651858.CD010051.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1089\/10807680260362696","article-title":"Blood concentrations of cyclosporin A during long-term treatment with cyclosporin A ophthalmic emulsions in patients with moderate to severe dry eye disease","volume":"18","author":"Small","year":"2002","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0063|cit63","first-page":"ARVO abstract 3","article-title":"Blood concentrations of cyclosporin A (CsA) during twice-daily treatment of 0.05% and 0.1% cyclosporine ophthalmic emulsions in patients with moderate to severe keratoconjunctivitis sicca","volume":"41","author":"Small","year":"2000","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/00003226-200007000-00018","article-title":"Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion","volume":"19","author":"Turner","year":"2000","journal-title":"Cornea"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0065|cit65","unstructured":"Whitcup SM Stern K Schiffman RM Topical cyclosporine 0.05% significantly improves Sj\u00f6gren's and non-Sj\u00f6gren's keratoconjunctivitis sicca American Academy of Ophthalmology San Francisco (CA) 2003 132"},{"issue":"5","key":"10.1002\/14651858.CD010051.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"520","DOI":"10.5301\/ejo.5000952","article-title":"A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye","volume":"27","author":"Baudouin","year":"2017","journal-title":"European Journal of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub3-BIB0067|cit67","first-page":"90","article-title":"Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A","volume":"42","author":"Brignole","year":"2001","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0068|cit68","first-page":"ARVO abstract 4","article-title":"Expression of inflammatory markers in dry eye syndrome following 12 months' treatment with topical cyclosporin","volume":"42","author":"Baudouin","year":"2001","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0069|cit69","first-page":"ARVO abstract 3","article-title":"Flow cytometric analysis of inflammatory markers in dry eyes: results of a six-month treatment with topical ciclosporin","volume":"41","author":"Baudouin","year":"2000","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"Pt B","key":"10.1002\/14651858.CD010051.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/978-1-4615-0717-8_107","article-title":"Flow cytometric analysis of the inflammatory marker HLA DR in dry eye syndrome: results from 12 months of randomized treatment with topical cyclosporin A","volume":"506","author":"Baudouin","year":"2002","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub3-BIB0071|cit71","first-page":"337","article-title":"Flow cytometry in impression cytology during keratoconjunctivitis sicca: effects of topical cyclosporin A on HLA DR expression","volume":"26","author":"Galatoire","year":"2003","journal-title":"Journal Francais d'Ophtalmologie"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","article-title":"Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial","volume":"26","author":"Leonardi","year":"2016","journal-title":"European Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD010051.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"678","DOI":"10.5301\/ejo.5001002","article-title":"One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease","volume":"27","author":"Baudouin","year":"2017","journal-title":"European Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD010051.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"678","DOI":"10.5301\/ejo.5001002","article-title":"One-year efficacy and safety of 0.1% cyclosporine a cationic emulsion in the treatment of severe dry eye disease","volume":"27","author":"Baudouin","year":"2017","journal-title":"European Journal of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"125-31","DOI":"10.1136\/bjophthalmol-2017-311801","article-title":"Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies","volume":"103","author":"Leonardi","year":"2019","journal-title":"British Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0076|cit76","unstructured":"A phase III, multicenter, randomized, controlled, double-masked trial of NOVA22007 (Ciclosporin 0.1%) ophthalmic cationic emulsion versus vehicle in patients with moderate to severe dry eye syndrome - SICCANOVE trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2007-000029-23-IT"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0077|cit77","unstructured":"6-months efficacy and safety clinical trial followed by 6-months of safety evaluation of CYCLOKAT\u00ae 1mg\/ml (ciclosporin) eye drops, emulsion administered once daily in adult patients with severe dry eye disease (DED) trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2011-000160-97-SE"},{"issue":"3","key":"10.1002\/14651858.CD010051.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3341\/kjo.2013.27.3.167","article-title":"The effect of topical cyclosporine 0.05% on dry eye after cataract surgery","volume":"27","author":"Chung","year":"2013","journal-title":"Korean Journal of Ophthalmology"},{"issue":"3","key":"10.1002\/14651858.CD010051.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"370-8","DOI":"10.1080\/09273948.2019.1587470","article-title":"Evaluation of the efficacy and safety of a novel 0.05% cyclosporin a topical nanoemulsion in primary Sj\u00f6gren's syndrome dry eye","volume":"28","author":"Kang","year":"2020","journal-title":"Ocular Immunology and Inflammation"},{"issue":"10","key":"10.1002\/14651858.CD010051.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/bjo.2008.150011","article-title":"A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome","volume":"94","author":"Baiza-Dur\u00e1n","year":"2010","journal-title":"British Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD010051.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/jop.2022.0183","article-title":"Efficacy of topical 0.05% cyclosporine A for ocular surface disease related to topical anti-glaucoma medications","volume":"39","author":"Kim","year":"2023","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0082|cit82","unstructured":"Treatment efficacy of 0.05% cyclosporine eyedrop on ocular surface changes after anti-glaucoma medication in glaucoma patients trialsearch.who.int\/Trial2.aspx?TrialID=KCT0007124"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00003226-199307000-00007","article-title":"Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca","volume":"12","author":"Laibovitz","year":"1993","journal-title":"Cornea"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0084|cit84","unstructured":"Study of two formulations of cyclosporine ophthalmic emulsion in healthy volunteers and in patients with dry eye clinicaltrials.gov\/study\/NCT01319773"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/vision7020031","article-title":"Effectiveness of topical cyclosporin-A 0.1% compared to combined topical cyclosporin-A 0.1% with topical sodium hyaluronate on interleukin-6 levels in the tears of patients with dry eye disease","volume":"7","author":"Priani","year":"2023","journal-title":"Vision"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/jop.2009.0145","article-title":"A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial","volume":"26","author":"Chen","year":"2010","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"31","key":"10.1002\/14651858.CD010051.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"e16710","DOI":"10.1097\/MD.0000000000016710","article-title":"Efficacy and safety of 0.05% cyclosporine ophthalmic emulsion in treatment of Chinese patients with moderate to severe dry eye disease: a 12-week, multicenter, randomized, double-masked, placebo-controlled phase III clinical study","volume":"98","author":"Chen","year":"2019","journal-title":"Medicine"},{"issue":"6","key":"10.1002\/14651858.CD010051.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1442-9071.2009.02090.x","article-title":"Efficacy of topical cyclosporine A in the treatment of severe trachomatous dry eye","volume":"37","author":"Guzey","year":"2009","journal-title":"Clinical & Experimental Ophthalmology"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1444-0938.2009.00369.x","article-title":"The effect of topical cyclosporine A treatment on corneal thickness in patients with trachomatous dry eye","volume":"92","author":"Guzey","year":"2009","journal-title":"Clinical & Experimental Optometry"},{"issue":"7","key":"10.1002\/14651858.CD010051.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.ophtha.2012.01.028","article-title":"Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1\/2 trial","volume":"119","author":"Liew","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD010051.pub3-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.ophtha.2012.03.017","article-title":"Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease","volume":"119","author":"Huang","year":"2012","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1002\/14651858.CD010051.pub3-BIB0092|cit92","first-page":"655","article-title":"Efficacy and safety of 0.05% cyclosporine A ophthalmic emulsion in treatment of dry eye","volume":"33","author":"Ma","year":"2015","journal-title":"Zhonghua Shiyan Yanke Zazhi [Chinese Journal of Experimental Ophthalmology]"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0093|cit93","unstructured":"A research study to see how well an eye drop, SURF-100 (a mycophenolic acid\/\u200bbetamethasone sodium phosphate combination), works and what side effects there are in subjects with dry eye disease https:\/\/clinicaltrials.gov\/study\/NCT04734197"},{"issue":"16","key":"10.1002\/14651858.CD010051.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.2147\/DDDT.S370559","article-title":"Cyclosporine A (0.05%) ophthalmic gel in the treatment of dry eye disease: a multicenter, randomized, double-masked, phase III, COSMO trial","volume":"20","author":"Peng","year":"2022","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0095|cit95","unstructured":"Assess the safety and efficacy of CsA ophthalmic gel in subjects with moderate to severe dry eye disease clinicaltrials.gov\/study\/NCT04541888"},{"issue":"5","key":"10.1002\/14651858.CD010051.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","article-title":"Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group","volume":"107","author":"Stevenson","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0097|cit97","first-page":"ARVO abstract 1","article-title":"The safety and efficacy of cyclosporine (0.05, 0.1, 0.2 and 0.4%) and vehicle ophthalmic emulsions in the treatment of moderate to severe keratoconjunctivitis sicca (KCS)","volume":"38","author":"Reis","year":"1997","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/978-1-4615-5359-5_138","article-title":"A dose-ranging clinical trial to assess the safety and efficacy of cyclosporine ophthalmic emulsion in patients with keratoconjunctivitis sicca. The Cyclosporine Study Group","volume":"438","author":"Tauber","year":"1998","journal-title":"Advances in Experimental Medicine and Biology"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2147\/OPTH.S175065","article-title":"Phase II\/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease","volume":"12","author":"Tauber","year":"2018","journal-title":"Clinical Ophthalmology"},{"issue":"16","key":"10.1002\/14651858.CD010051.pub3-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.2147\/OPTH.S392315","article-title":"Effect of OTX-101 in patients with dry eye disease at day 14 of treatment: ocular surface endpoint results from the Phase 2b\/3 clinical trial","volume":"13","author":"Schechter","year":"2022","journal-title":"Clinical Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0101|cit101","unstructured":"Phase 2\/\u200b3 dose-ranging study of the safety and efficacy of OTX-101 in the treatment of keratoconjunctivitis sicca clinicaltrials.gov\/study\/NCT02254265"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12886-024-03620-5","article-title":"Effectiveness of cyclosporine nanoemulsion eye drops in patients with mild-to-moderate dry eyes: objective and subjective evaluation","volume":"24","author":"Moon","year":"2024","journal-title":"BMC Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jtos.2023.04.015","article-title":"Proteomic analysis of tears in dry eye disease: a prospective, double-blind multicenter study","volume":"29","author":"Jung","year":"2023","journal-title":"Ocular Surface"},{"issue":"7","key":"10.1002\/14651858.CD010051.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1089\/jop.2016.0164","article-title":"Evaluation of clinical efficacy and safety of a novel cyclosporin A nanoemulsion in the treatment of dry eye syndrome","volume":"33","author":"Kim","year":"2017","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub3-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3341\/kjo.2018.0116","article-title":"Efficacy of topical cyclosporine nanoemulsion 0.05% compared with topical cyclosporine emulsion 0.05% and diquafosol 3% in dry eye","volume":"33","author":"Park","year":"2019","journal-title":"Korean Journal of Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0106|cit106","unstructured":"A multicenter, randomized, partial double blind, active control, parallel clinical trial to evaluate the efficacy, safety and usability of cyclosporin ophthalmic nanoemulsion 0.05%; compared with cyclosporin ophthalmic emulsion 0.05% and diquafosol ophthalmic solution https:\/\/cris.nih.go.kr\/cris\/search\/detailSearch.do?seq=10145&search_page=L&search_lang=E&lang=E&latest=Y"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub3-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12886-023-02838-z","article-title":"Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial","volume":"23","author":"Rao","year":"2023","journal-title":"BMC Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0108|cit108","unstructured":"This study compares the effectiveness and safety of the study product cylclosporin against Restasis in patients suffering from moderate to severe dry eye trialsearch.who.int\/Trial2.aspx?TrialID=CTRI\/2019\/03\/018319"},{"issue":"5","key":"10.1002\/14651858.CD010051.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaophthalmol.2023.0709","article-title":"Efficacy and safety of a water-free topical cyclosporine, 0.1%, solution for the treatment of moderate to severe dry eye disease: the ESSENCE-2 randomized clinical trial","volume":"14","author":"Akpek","year":"2023","journal-title":"JAMA Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0110|cit110","unstructured":"ESSENCE 2: CyclASol for the treatment of signs and symptoms of Dry Eye Disease (DED) clinicaltrials.gov\/study\/NCT04523129"},{"issue":"6","key":"10.1002\/14651858.CD010051.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/ICO.0000000000003567","article-title":"Long-term safety and efficacy of a water-free cyclosporine 0.1% ophthalmic solution for treatment of dry eye disease: ESSENCE-2 OLE","volume":"44","author":"Wirta","year":"2024","journal-title":"Cornea"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jamaophthalmol.2024.0101","article-title":"Water-free cyclosporine ophthalmic solution vs vehicle for dry eye disease: a randomized clinical trial","volume":"142","author":"Peng","year":"2024","journal-title":"JAMA Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0113|cit113","unstructured":"Efficacy and safety of SHR8028 eye drops for the treatment of dry eye disease clinicaltrials.gov\/study\/NCT05841043"},{"issue":"10","key":"10.1002\/14651858.CD010051.pub3-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1097\/ICO.0000000000002633","article-title":"A water-free 0.1% cyclosporine A solution for treatment of dry eye disease: results of the randomized phase 2B\/3 ESSENCE study","volume":"40","author":"Sheppard","year":"2021","journal-title":"Cornea"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0115|cit115","unstructured":"Kaercher T Sheppard JD Hamm A Akpek EK Kr\u00f6sser S Pooled results from two pivotal randomized controlled clinical trials: ESSENCE-1 and ESSENCE-2 to assess efficacy and safety of a water-free ciclosporin 0.1% formulation for the treatment of dry eye disease Graefe's Archive for Clinical and Experimental Ophthalmology 10.1007\/s00417-024-06688-3"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0116|cit116","unstructured":"CyclASol for the treatment of signs and symptoms of dry eye disease (DED) clinicaltrials.gov\/ct2\/show\/NCT03292809"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.ophtha.2019.03.050","article-title":"A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease","volume":"9","author":"Goldberg","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/OPTH.S279364","article-title":"Phase 3 efficacy (worse-eye analysis) and long-term safety evaluation of OTX-101 in patients with keratoconjunctivitis sicca","volume":"15","author":"Sheppard","year":"2021","journal-title":"Clinical Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0119|cit119","unstructured":"Phase 3 study of OTX-101 in the treatment of keratoconjunctivitis sicca (Emerald) clinicaltrials.gov\/study\/NCT02688556"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub3-BIB0120|cit120","first-page":"85","article-title":"Topical cyclosporine therapy for keratoconjunctivitis sicca in Sjogrens' syndrome","volume":"15","author":"Fan","year":"2003","journal-title":"Tzu Chi Medical Journal"},{"issue":"12","key":"10.1002\/14651858.CD010051.pub3-BIB0121|cit121","first-page":"1685-91","article-title":"Comparative evaluation of efficacy and safety of cyclosporine 0.1% add-on therapy with artificial tears (carboxymethylcellulose 0.5%) with artificial tears alone in post cataract surgery patients","volume":"8","author":"Kudyar","year":"2018","journal-title":"National Journal of Physiology, Pharmacy and Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD010051.pub3-BIB0122|cit122","first-page":"1031-4","article-title":"Clinical effect of sodium hyaluronate and cyclosporine A eye drops for combination treatment of mixed dry eye syndrome","volume":"20","author":"Shen","year":"2020","journal-title":"International Eye Science"},{"issue":"4","key":"10.1002\/14651858.CD010051.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1755-3768.1994.tb02792.x","article-title":"Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sj\u00f6gren's syndrome","volume":"72","author":"G\u00fcnd\u00fcz","year":"1994","journal-title":"Acta Ophthalmologica"},{"issue":"8","key":"10.1002\/14651858.CD010051.pub3-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1080\/09273948.2022.2094812","article-title":"Evaluation of the efficacy and safety of topical 0.05% cyclosporine eye drops (II) in the treatment of dry eye associated with primary Sj\u00f6gren's syndrome","volume":"31","author":"Gao","year":"2023","journal-title":"Ocular Immunology and Inflammation"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub3-BIB0125|cit125","first-page":"127","article-title":"Efficacy of 0.05% cyclosporine A combined with vitamin A palmitate in the treatment of meibomian gland dysfunction\u2011related dry eye","volume":"60","author":"Hao","year":"2024","journal-title":"Zhonghua Yan Ke Za Zhi"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0126|cit126","unstructured":"Efficacy analysis of 0.05% cyclosporine eye drops (II) on dry eyes related to meibomian gland dysfunction and study on metabolic regulation network and molecular mechanism of meibomian gland dysfunction www.chictr.org.cn\/showprojEN.html?proj=131089"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0127|cit127","unstructured":"Comparison of vitamin A and cyclosporin 0.05% eye drops for treatment of dry eye syndrome trialsearch.who.int\/Trial2.aspx?TrialID=ISRCTN47762748"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub3-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ajo.2008.08.015","article-title":"A comparison of vitamin A and cyclosporine A 0.05% eye drops for treatment of dry eye syndrome","volume":"147","author":"Kim","year":"2009","journal-title":"American Journal of Ophthalmology"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"18737","DOI":"10.1038\/s41598-022-21330-0","article-title":"A randomized multicenter evaluation of the efficacy of 0.15% hyaluronic acid versus 0.05% cyclosporine A in dry eye syndrome","volume":"12","author":"Lee","year":"2022","journal-title":"Scientific Reports"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0130|cit130","unstructured":"Evaluating HA 0.15% compared with cyclosporine 0.05%, and efficacy of combination therapy in dry eye disease patients clinicaltrials.gov\/study\/NCT04127851"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub3-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1089\/jop.2016.0086","article-title":"A randomized multicenter study comparing 0.1%, 0.15%,and 0.3% sodium hyaluronate with 0.05% cyclosporinein the treatment of dry eye","volume":"33","author":"Park","year":"2017","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0132|cit132","unstructured":"Clinical efficacy and safety of sodium hyaluronates in different concentration and cyclosporine 0.05% in patients with dry eye trialsearch.who.int\/Trial2.aspx?TrialID=KCT0001796"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/jop.2009.0091","article-title":"Topical cyclosporine 0.05% for the prevention of dry eye disease progression","volume":"26","author":"Rao","year":"2010","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0134|cit134","unstructured":"Asano K Rao S Topical cyclosporine for the prevention of dry eye disease: second year of two-year study American Academy of Optometry Orlando (FL) 2009"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0135|cit135","unstructured":"Topical cyclosporine and disease progression clinicaltrials.gov\/study\/NCT00567983"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0136|cit136","unstructured":"Rao S Prevention of dry eye disease progression by topical cyclosporine 0.05% American Academy of Ophthalmology San Francisco (CA) 2008 202"},{"issue":"6","key":"10.1002\/14651858.CD010051.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1089\/jop.2011.0073","article-title":"Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal","volume":"27","author":"Rao","year":"2011","journal-title":"Journal of Ocular Pharmacology & Therapeutics"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0138|cit138","first-page":"ARVO abstract 2","article-title":"The impact of topical cyclosporine 0.05% on dry eye and daily activity","volume":"47","author":"Rao","year":"2006","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0139|cit139","first-page":"ARVO abstract 1","article-title":"Topical cyclosporine 0.05% for the prevention of dry eye disease progression","volume":"49","author":"Rao","year":"2008","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"5","key":"10.1002\/14651858.CD010051.pub3-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jcrs.2005.10.034","article-title":"Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis","volume":"32","author":"Salib","year":"2006","journal-title":"Journal of Cataract and Refractive Surgery"},{"issue":"5","key":"10.1002\/14651858.CD010051.pub3-BIB0141|cit141","first-page":"548","article-title":"Topical cyclosporine A 0.05% in the treatment of keratoconjunctivitis sicca","volume":"229","author":"Schrell","year":"2012","journal-title":"Klinische Monatsblatter fur Augenheilkunde"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub3-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/ICL.0b013e3180676d44","article-title":"Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes","volume":"34","author":"Willen","year":"2008","journal-title":"Eye & Contact Lens"},{"issue":"5","key":"10.1002\/14651858.CD010051.pub3-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/ICL.0b013e31822563be","article-title":"Effects of topical cyclosporine A plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome","volume":"37","author":"Demiryay","year":"2011","journal-title":"Eye & Contact Lens"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0144|cit144","unstructured":"Efficacy of 0.05 % cyclosporine ophthalmic emulsion compare with tear in meibomian gland dysfunction clinicaltrials.gov\/show\/NCT00705510"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/ICO.0b013e31823cc098","article-title":"A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction","volume":"31","author":"Prabhasawat","year":"2012","journal-title":"Cornea"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub3-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.icl.0000170599.57728.29","article-title":"An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye","volume":"32","author":"Sall","year":"2006","journal-title":"Eye & Contact Lens"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0147|cit147","doi-asserted-by":"crossref","unstructured":"Christensen M Hearn C Tudor M Stein J Meadows D Stone R Efficacy of a cyclosporine-based dry eye therapy with two marketed artificial tears as supportive therapy American Academy of Optometry Orlando (FL) 2004","DOI":"10.1016\/S1542-0124(12)70377-4"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0148|cit148","first-page":"ARVO abstract 2","article-title":"Efficacy and compatibility of an HP-guar based lubricant eye drop when used as supportive therapy with a cyclosporine-based ophthalmic emulsion","volume":"46","author":"Sall","year":"2005","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"2","key":"10.1002\/14651858.CD010051.pub3-BIB0149|cit149","first-page":"389","article-title":"Effect of cyclosporin A in the treatment of severe dry eye syndrome","volume":"9","author":"Wu","year":"2009","journal-title":"International Journal of Ophthalmology"},{"issue":"6","key":"10.1002\/14651858.CD010051.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/eye.2009.246","article-title":"Topical cyclosporine A for the dry eye findings of thyroid orbitopathy patients","volume":"24","author":"Altiparmak","year":"2010","journal-title":"Eye (London, England)"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0151|cit151","unstructured":"Chen KY Chan HC Chan CM Which topical ophthalmic drugs work best for Keratoconjunctivitis Sicca? A systematic review and meta-analysis Naunyn-Schmiedeberg's Archives of Pharmacology 10.1007\/s00210-025-04454-8"},{"issue":"5","key":"10.1002\/14651858.CD010051.pub3-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/ceo.14514","article-title":"Evidence on the use of topical ciclosporin for ocular surface disease: a systematic review and meta-analysis","volume":"53","author":"Chidi-Egboka","year":"2025","journal-title":"Clinical & Experimental Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40495-025-00393-3","article-title":"Efficacy and safety of topical cyclosporine A in moderate-to-severe dry eye disease: an updated systematic review with meta-analysis","volume":"11","author":"Eng","year":"2025","journal-title":"Current Pharmacology Reports"},{"issue":"6","key":"10.1002\/14651858.CD010051.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/jop.2024.0192","article-title":"Comparative efficacy of current topical treatments for dry eye disease: a review of pivotal clinical trials evaluating corneal staining outcomes","volume":"41","author":"Fahmy","year":"2025","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub3-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10792-025-03570-x","article-title":"Efficacy of topical cyclosporine A in optimizing ocular surface and relieving dry eye symptoms after cataract surgery: a systematic review and meta-analysis of randomized controlled trials","volume":"45","author":"Lu","year":"2025","journal-title":"International Ophthalmology"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/DDDT.S207743","article-title":"An updated systematic review with meta-analysis of randomized trials on topical cyclosporin A for dry-eye disease","volume":"14","author":"Tuan","year":"2020","journal-title":"Drug Design, Development and Therapy"},{"issue":"1","key":"10.1002\/14651858.CD010051.pub3-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12348-025-00467-9","article-title":"Efficacy and safety of water-free topical cyclosporine for moderate to severe dry eye disease: a systematic review and meta-analysis","volume":"15","author":"Rehan","year":"2025","journal-title":"Journal of Ophthalmic Inflammation and Infection"},{"key":"10.1002\/14651858.CD010051.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"882803","DOI":"10.3389\/fphar.2022.882803","article-title":"Comparison of seven cyclosporine A formulations for dry eye disease: a systematic review and network meta-analysis","volume":"13","author":"Gao","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"10","key":"10.1002\/14651858.CD010051.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1007\/s40123-025-01217-9","article-title":"Assessment the safety of cyclASol compared with vehicle and commercially available 0.05% cyclosporine in dry eye disease: a systematic review and meta-analysis","volume":"14","author":"Ballesteros-S\u00e1nchez","year":"2025","journal-title":"Ophthalmology and Therapy"},{"issue":"9","key":"10.1002\/14651858.CD010051.pub3-BIB0160|cit160","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010051","article-title":"Topical cyclosporine Atherapy for dry eye syndrome","author":"De Paiva","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:34:01Z","timestamp":1788503641000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010051.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":160,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010051.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]}}}